Chromatin modifiers and the promise of epigenetic therapy in acute leukemia von Greenblatt, S M, Nimer, S D

Volltext

Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML von Kaushik, S, Liu, F, Veazey, K J, Gao, G, Das, P, Neves, L F, Lin, K, Zhong, Y, Lu, Y, Giuliani, V, Bedford, M T, Nimer, S D, Santos, M A

Volltext

Histone H4 lysine 20 monomethylation promotes transcriptional repression by L3MBTL1 von Kalakonda, N, Fischle, W, Boccuni, P, Gurvich, N, Hoya-Arias, R, Zhao, X, Miyata, Y, MacGrogan, D, Zhang, J, Sims, J K, Rice, J C, Nimer, S D

Volltext

Loss of p300 accelerates MDS-associated leukemogenesis von Cheng, G, Liu, F, Asai, T, Lai, F, Man, N, Xu, H, Chen, S, Greenblatt, S, Hamard, P-J, Ando, K, Chen, X, Wang, L, Martinez, C, Tadi, M, Wang, L, Xu, M, Yang, F-C, Shiekhattar, R, Nimer, S D

Volltext

Report of an international working group to standardize response criteria for myelodysplastic syndromes von Cheson, Bruce D., Bennett, John M., Kantarjian, Hagop, Pinto, Antonio, Schiffer, Charles A., Nimer, Stephen D., Löwenberg, Bob, Beran, Miroslav, de Witte, Theo M., Stone, Richard M., Mittelman, Moshe, Sanz, Guillermo F., Wijermans, Pierre W., Gore, Steven, Greenberg, Peter L.

Volltext

Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma von KEWALRAMANI, T, NIMER, S. D, ZELENETZ, A. D, MALHOTRA, S, QIN, J, YAHALOM, J, MOSKOWITZ, C. H

Volltext

High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease von Hassoun, H, Flombaum, C, D'Agati, V D, Rafferty, B T, Cohen, A, Klimek, V M, Boruchov, A, Kewalramani, T, Reich, L, Nimer, S D, Comenzo, R L

Volltext

Tumor promoting properties of the ETS protein MEF in ovarian cancer von YAO, J. J, LIU, Y, LACORAZZA, H. D, SOSLOW, R. A, SCANDURA, J. M, NIMER, S. D, HEDVAT, C. V

Volltext

Retrospective comparison of the effects of filgrastim and pegfilgrastim on the pace of engraftment in auto-SCT patients von Mathew, S, Adel, N, Rice, R D, Panageas, K, Duck, E T, Comenzo, R L, Kewalramani, T, Nimer, S D

Volltext

Ifosfamide, Carboplatin, and Etoposide: A Highly Effective Cytoreduction and Peripheral-Blood Progenitor-Cell Mobilization Regimen for Transplant-Eligible Patients With Non-Hodgkin... von MOSKOWITZ, C. H, BERTINO, J. R, O'BRIEN, J, PORTLOCK, C. S, STRAUS, D. S, CHILDS, B, FRANK, R, YAHALOM, J, FILIPPA, D, LOUIE, D, NIMER, S. D, ZELENETZ, A. D, GLASSMAN, J. R, HEDRICK, E. E, HUNTE, S, COADY-LYONS, N, AGUS, D. B, GOY, A, JURCIC, J, NOY, A

Volltext

Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia von Shih, Alan H, Chung, Stephen S, Dolezal, Emily K, Zhang, Su-Jiang, Abdel-Wahab, Omar I, Park, Christopher Y, Nimer, Stephen D, Levine, Ross L, Klimek, Virginia M

Volltext

Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymph... von Moskowitz, C. H., Hamlin, P. A., Gabrilove, J., Bertino, J. R., Portlock, C. S., Straus, D. J., Gencarelli, A. N., Nimer, S. D., Zelenetz, A. D.

Volltext

Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS von List, A F, Bennett, J M, Sekeres, M A, Skikne, B, Fu, T, Shammo, J M, Nimer, S D, Knight, R D, Giagounidis, A

Volltext

Autologous stem cell transplantation in multiple myeloma patients <60 vs ≥60 years of age von REECE, D. E, BREDESON, C, GIBSON, J, GIRALT, S. A, KEATING, A, KYLE, R. A, MAHARAJ, D, MARCELLUS, D, MCCARTHYL, P. L, MILONE, G. A, NIMER, S. D, PAVLOVSKY, S, PEREZ, W. S, TO, L. B, WEISDORF, D. J, WIERNIK, P. H, WINGARD, J. R, VESOLE, D. H, JAGANNATH, S, ZHANG, M. J, BALLEN, K. K, ELFENBEIN, G. J, FREYTES, C. O, GALE, R. P, GERTZ, M. A

Volltext

Two cell lines of t(8;21) acute myeloid leukemia with activating KIT exon 17 mutation: models for the 'second hit' hypothesis von Becker, H, Pfeifer, D, Afonso, J D, Nimer, S D, Veelken, H, Schwabe, M, Lübbert, M

Volltext

Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma von MOSKOWITZ, C. H, GLASSMAN, J. R, WUEST, D, MASLAK, P, REICH, L, GUCCIARDO, A, COADY-LYONS, N, ZELENETZ, A. D, NIMER, S. D

Volltext

Phosphoproteomic analysis identifies the M0-91 cell line as a cellular model for the study of TEL-TRKC fusion-associated leukemia von Gu, T-L, Popova, L, Reeves, C, Nardone, J, Macneill, J, Rush, J, Nimer, S D, Polakiewicz, R D

Volltext

Results of a phase I II trial adding carmustine (300 mg m ) to melphalan (200 mg m ) in multiple myeloma patients undergoing autologous stem cell transplantation von COMENZO, R. L, HASSOUN, H, KEWALRAMANI, T, KLIMEK, V, DHODAPKAR, M, REICH, L, TERUYA-FELDSTEIN, J, FLEISHIAR, M, FILIPPA, D, NIMER, S. D

Volltext

AML1A and AML1B can transactivate the human IL-3 promoter von Uchida, H, Zhang, J, Nimer, SD

Volltext

Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS von List, A F, Bennett, J M, Sekeres, M A, Skikne, B, Fu, T, Shammo, J M, Nimer, S D, Knight, R D, Giagounidis, A

Volltext